<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810704</url>
  </required_header>
  <id_info>
    <org_study_id>1402</org_study_id>
    <nct_id>NCT02810704</nct_id>
  </id_info>
  <brief_title>Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement</brief_title>
  <acronym>PEPPER</acronym>
  <official_title>Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement: Balancing Safety and Effectiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PEPPER is a randomized study comparing the three most commonly used anticoagulants in North
      America in patients who have elected to undergo primary or revision hip or knee joint
      replacement surgery. The anticoagulants being compared are enteric coated aspirin, low
      intensity warfarin, and rivaroxaban.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PEPPER is a large pragmatic clinical trial to inform patient choice and balance risk
      tolerances of individuals who face decisions about different drugs and strategies for deep
      vein thrombosis (DVT) and pulmonary embolism (PE) prevention after total hip (THA) and knee
      (TKA) replacement. Indeed, clinical equipoise exists to ethically support such a randomized
      trial that has great potential to change current practice. We have selected the three
      prophylaxis methods that represent current orthopaedic practice in North America and
      collectively account for more than 80% of all hip and knee replacements; a) enteric coated
      aspirin (regimen with lowest bleeding risk; clinical PE and all-cause mortality rates
      comparable to more intensive anticoagulants), b) low intensity (INR Target 2.0) warfarin
      (time honored and one of the most common North American regimens; low bleeding risk [1-2%]),
      and c) rivaroxaban, a new oral direct Factor Xa inhibitor (regimen with lowest PE and DVT
      rate but higher bleeding risk [3-5%]). Prophylaxis will continue for 30 days, in accordance
      with clinical guidelines, and pneumatic compression will be utilized in hospital in
      conjunction with each treatment group. Each regimen is commonly used in contemporary
      practice, supported by observational and clinical trial data, and endorsed by the American
      College of Chest Physicians (ACCP) and American Academy of Orthopaedic Surgeons (AAOS)
      guidelines
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aggregate primary clinical endpoints of all-cause mortality plus PE and DVT</measure>
    <time_frame>Within 6 months of operation</time_frame>
    <description>To compare the frequency of the aggregate primary clinical endpoints of important venous thromboembolism (clinical PE and DVT leading to hospital readmission) and all-cause mortality (aggregate indicator of fatal events, including both PE and major hemorrhage related to anticoagulant use) among three different venous thromboembolism (VTE) prophylaxis regimens. An audit of all hospital readmissions within 6 months of operation will be accomplished by routine postoperative follow-up through a mechanism of central telephone surveillance of patient-reported outcome events that is augmented by on-site research coordinator follow-up and validation of suspected endpoint events and adverse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The frequency and nature of bleeding complications</measure>
    <time_frame>Within 6 months of operation</time_frame>
    <description>To compare the frequency and nature of bleeding complications (major, clinically important, and wound-related) leading to wound drainage, reoperation, or deep infection, or myocardial infarction among three different VTE prophylaxis regimens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specific Joint Function</measure>
    <time_frame>Within 6 months of operation</time_frame>
    <description>To compare the groups with respect to patient-reported outcomes in order to assess their impact on specific function of the replaced joint. Validated functional outcome tools will be compared among patients with and without primary endpoint events, as well as with historical baseline data warehoused in the FORCE registry, a national AHRQ funded joint replacement outcomes database. Study site overlap with the FORCE registry is planned.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Well- Being</measure>
    <time_frame>Within 6 months of operation</time_frame>
    <description>To compare the groups with respect to patient-reported outcomes in order to assess their impact on general patient well-being. Validated functional outcome tools will be compared among patients with and without primary endpoint events, as well as with historical baseline data warehoused in the FORCE registry, a national AHRQ funded joint replacement outcomes database. Study site overlap with the FORCE registry is planned.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&quot;Standard of care&quot; methods of anesthesia on clinical effectiveness of three different prophylaxis regimens based on adverse events</measure>
    <time_frame>Within 6 months of operation</time_frame>
    <description>Analysis of the contribution of &quot;standard of care&quot; methods of anesthesia on clinical effectiveness of three different prophylaxis regimens. Stratification and subgroup analysis between patients with general compared with regional neuraxial (spinal/epidural) anesthesia will assess contribution of anesthesia to efficacy of VTE prophylaxis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative frequency of thromboembolic events and bleeding complications occurring after hip and knee replacement</measure>
    <time_frame>Within 6 months of operation</time_frame>
    <description>Analysis of the the relative frequency of thromboembolic events and bleeding complications in total hip compared with knee replacement patients. Evidence suggests etiology of venous thromboembolic disease (VTED) differs between THA and TKA and each may warrant a distinctive prophylaxis regimen based on likely outcomes.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25000</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Arm 1: Enteric Coated Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enteric coated aspirin (162 mg po) will be administered on the day of operation, prior to surgery, with a sip of water. Thereafter, starting on postoperative day #1, all patients in the aspirin group will receive 81 mg po bid to complete the treatment period of 30 days. Patients on preoperative cardiac dose aspirin may continue their usual dosing regimen prior to the morning of surgery, and then commence the PEPPER trial aspirin dose of 81 mg po bid on the day after operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Warfarin Other Names: Coumadin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Warfarin will be administered starting on the day of operation, prior to surgery, with a sip of water. The initial dose will be empirically determined by body weight: less than 125 lbs (56.7 kg) - 2.5 mg; 125-250 lbs (56.7-113.4 kg) - 5 mg; greater than 250 lbs (113.4 kg) - 7.5mg. The initial dose will be repeated on the evening of surgery if the preoperative dose was administered prior to noon on the day of operation; no warfarin will be given on the evening of surgery if the preoperative dose was received after noon on the day of operation. Thereafter, starting on postoperative day #1, warfarin will be given each evening based on INR values to achieve a target of 2.0 (range 1.7-2.2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Rivaroxaban Other Names: Xarelto</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 10 mg will be first administered approximately 24 hours after completion of the index operation. Medication will then be administered in the evening on postoperative day #2 and thereafter each evening until completion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric Coated Aspirin</intervention_name>
    <arm_group_label>Arm 1: Enteric Coated Aspirin</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <arm_group_label>Arm 2: Warfarin Other Names: Coumadin</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <arm_group_label>Arm 3: Rivaroxaban Other Names: Xarelto</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females 21 years of age or older;

          2. Undergoing elective primary, resurfacing arthroplasty, revision, or second stage
             re-implantation total hip replacement;

          3. Undergoing elective primary, revision, or second stage re-implantation total or uni
             compartmental knee replacement;

          4. Patient has necessary mental capacity to participate and is able to comply with study
             protocol requirements;

          5. Patient is willing and able to give informed consent; and

          6. Patient is willing to be randomized and participate.

        Exclusion Criteria:

          1. Patients undergoing bilateral hip or knee replacement;

          2. Patients undergoing total hip or knee replacement who have been enrolled in this study
             for a prior hip or knee replacement;

          3. Patients who are concurrently enrolled in another active interventional clinical trial
             testing a drug or intervention known or believed to interact with aspirin, warfarin,
             or rivaroxaban;

          4. Patients who have a contraindication to two or more of the three study prophylaxis
             regimens;

          5. Women who are pregnant or breastfeeding, as well as those of reproductive potential
             unless there is a negative urine pregnancy test on the day of surgery;

          6. Patients on chronic (longer than the prior 6 months) anticoagulation other than with
             antiplatelet medications;

          7. Patients with documented gastrointestinal, cerebral, or other hemorrhage within 3
             months of the operation;

          8. Patients with a known diagnosis of defective hemostasis and past history of clinical
             bleeding requiring transfusion and treatment;

          9. Patients who have had an operative procedure involving the eye, ear, or central
             nervous system within one month;

         10. Patients with severe uncontrolled hypertension with systolic BP &gt; 220mmHg or diastolic
             BP &gt; 120mmHg;

         11. Patients with an absolute body weight of less than 41 kilograms (90.4 lbs) at baseline
             visit;

         12. Vulnerable patient populations including prisoners and institutionalized individuals.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent D Pellegrini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carol A Lambourne, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica E Baczko, MPA</last_name>
    <phone>843-792-8169</phone>
    <email>baczko@musc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Azevedo</last_name>
      <email>azevedo.cindy@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Spangehl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Wilson</last_name>
      <email>bwilson@hipkneearkansas.com</email>
    </contact>
    <investigator>
      <last_name>C. Lowry Barnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bert Thomas</last_name>
      <email>bthomas@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Bert Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Maloney</last_name>
      <email>wmaloney@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>William Maloney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Surgery Research Foundation</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Lavernia</last_name>
      <email>c@drlavernia.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Lavernia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Sporer</last_name>
      <email>scott.sporer@rushortho.com</email>
    </contact>
    <investigator>
      <last_name>Joshua Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gesheff</last_name>
      <email>mgesheff@lifebridgehealth.org</email>
    </contact>
    <investigator>
      <last_name>James Nace, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Sterling</last_name>
      <email>rsterli6@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Sterling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Garfi</last_name>
      <email>john.garfi@lahey.org</email>
    </contact>
    <investigator>
      <last_name>Lawrence Specht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teron Cox</last_name>
      <email>cox.teron@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Perry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tad Mabry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Schwartz</last_name>
      <email>dschwarz@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Garvin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Mack</last_name>
      <email>lisa.a.mack@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Wayne Moschetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Iorio</last_name>
      <email>richard.iorio@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Richard Iorio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Harlin</last_name>
      <email>joanne.harlin@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Bolognesi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Klika</last_name>
      <phone>216-444-4954</phone>
      <email>klikaa@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Michael Mont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa K Swenson</last_name>
      <phone>570-214-6178</phone>
      <email>tkswenson@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Suk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Med Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Davis</last_name>
      <email>cdavis2@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Davis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Moses</last_name>
      <phone>267-207-6254</phone>
      <email>helena.moses@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Charles L Nelson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica E Baczko, MPA</last_name>
      <phone>843-792-8169</phone>
      <email>baczko@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Friedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anderson Orthopaedic Institute (VA)</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Supatra Sritulanondha</last_name>
      <email>supatras@aori.org</email>
    </contact>
    <investigator>
      <last_name>Kevin Fricka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric McVey</last_name>
      <email>emcvey@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>James Browne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Morgan</last_name>
      <email>melanie.morgan@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Kates, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann M Chancellor</last_name>
      <phone>206-520-5740</phone>
      <email>achance@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Navin D Fernando, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Eicher</last_name>
      <email>jeicher@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Brock Lindsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyndsay Somerville</last_name>
      <email>lyndsay.somerville@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Brent Lanting, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anticoagulant</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Total Knee Arthroplasty</keyword>
  <keyword>Total Hip Arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data Sharing Plan: The participating institutions will follow NIH guidelines concerning the sharing of research data. As outlined by the NIH and PCORI, the participating institutions will make available to the public the results of this collaboration and any accompanying data that were supported by PCORI. There are no specimens or biological resources for sharing as a result of this planned project.
In the course of this research project, we anticipate generating ranges of estimated complications and adverse events as they relate to the use of VTE prophylaxis in the context of hip and knee replacement. Access to these data and associated recommendations generated under the project will be available for educational, research and non-profit purposes. Such access will be provided using web-based applications, as appropriate and consistent with the data distribution policies of the Medical University of South Carolina and the University of Maryland.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

